{
    "Trade/Device Name(s)": [
        "Applied Biosystems\u2122 3500 Dx Genetic Analyzer",
        "Applied Biosystems\u2122 3500xL Dx Genetic Analyzer"
    ],
    "Submitter Information": "Life Technologies Corporation",
    "510(k) Number": "K191030",
    "Predicate Device Reference 510(k) Number(s)": [
        "BK110039"
    ],
    "Regulatory Class": "Class II exempt, meets the limitation of exemptions 21 CFR 862.9(a)",
    "Product Code(s)": [
        "PCA"
    ],
    "Summary Letter Date": "February 21, 2020",
    "Summary Letter Received Date": "February 4, 2020",
    "Submission Date": "February 18, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.2570"
    ],
    "Regulation Name(s)": [
        "Instrumentation For Clinical Multiplex Test Systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular"
    ],
    "Analyte(s)": [
        "Human genomic deoxyribonucleic acid (DNA) nucleotides"
    ],
    "Specimen Type(s)": [
        "DNA"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Applied Biosystems\u2122 3500 Dx Genetic Analyzer",
        "Applied Biosystems\u2122 3500xL Dx Genetic Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Capillary electrophoresis",
        "Fluorescence-based DNA analysis"
    ],
    "Methodologies": [
        "Sequencing",
        "Fragment analysis"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Instrument",
        "Software",
        "Consumable",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Applied Biosystems 3500 Dx and 3500xL Dx Genetic Analyzers for sequencing and fragment analysis of fluorescently labeled human genomic DNA by capillary electrophoresis.",
    "Indications for Use Summary": "Indicated for sequencing and fragment analysis of fluorescently-labeled human genomic DNA nucleotides using FDA-cleared or approved assays by capillary electrophoresis.",
    "fda_folder": "Clinical Chemistry"
}